Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 1 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM003766
Első szerző:
Szűk Tibor (kardiológus)
Cím:
Effect of timing of clopidogrel administration on 30-day clinical outcomes : 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort / Szuk, T., Gyongyosi, M., Homorodi, N., Kristof, E., Kiraly, C., Edes, I. F., Facsko, A., Pavo, N., Sodeck, G., Strehblow, C., Farhan, S., Maurer, G., Glogar, D., Domanovits, H., Huber, K., Edes, I.
Dátum:
2007
Megjegyzések:
The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting. METHODS: Between March 2002 and February 2004, 4160 consecutively included patients received a 300-mg loading dose of clopidogrel immediately after (group 1, n = 2679) or 6 to 24 hours before stenting (group 2, n = 1481). RESULTS: The primary end point (triple composite end point of acute myocardial infarction, all-cause death, and urgent repeat target vessel revascularization) at 30 days occurred in 4.74% versus 2.77% in groups 1 and 2, respectively (P = .002). The secondary end point events, the stent thrombosis, occurred significantly more frequently in group 1, with a trend toward increase in incidence of death, target vessel revascularization, or need for glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention. Pretreatment with clopidogrel was associated with more major bleeding (secondary safety end point) (0.41% vs 1.35% in groups 1 and 2, respectively; P = .001). CONCLUSIONS: The results of our multicenter prospective Clopidogrel Registry demonstrate lower efficacy of a 300-mg loading dose of clopidogrel at the time of stenting compared with pretreatment 6 to 24 hours before percutaneous coronary intervention on the 30-day composite clinical end point in the large unselected patient cohort, which suggests the benefit of clopidogrel pretreatment in all incoming patients with suspected significant coronary artery disease scheduled for coronary angiography
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
administration &
analogs &
Combined Modality Therapy
Coronary Angiography
Coronary Artery Disease
derivatives
dosage
Drug Administration Schedule
drug therapy
Female
Humans
Male
methods
Middle Aged
Myocardial Infarction
Myocardial Revascularization
Platelet Aggregation Inhibitors
Preoperative Care
Prospective Studies
Registries
Stents
surgery
Ticlopidine
Time Factors
Treatment Outcome
Megjelenés:
American Heart Journal. - 153 : 2 (2007), p. 289-295. -
További szerzők:
Gyöngyösi Mariann
Homoródi Nóra (1974-) (kardiológus)
Kristóf Éva (1963-) (kardiológus)
Király Csaba
Édes István Ferenc (1980-) (kardiológus)
Facskó Andrea (1953-) (szemész)
Pavo, Noemi
Sodeck, Gottfried
Strehblow, Christoph
Farhan, Serdar
Maurer, Gerald
Glogar, Dietmar
Domanovits, Hans
Huber, Kurt
Édes István (1952-) (kardiológus)
Internet cím:
elektronikus változat
DOI
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.